Previous close | 49.05 |
Open | 49.05 |
Bid | 49.55 x 0 |
Ask | 49.65 x 0 |
Day's range | 49.05 - 49.05 |
52-week range | 44.55 - 64.20 |
Volume | |
Avg. volume | 81 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 25 Apr 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced fiscal year 2023 financial results for the period ended December 31, 2023. “We made tremendous progress during 2023 in building a fully integrated radiopharmaceuticals company dedicated to advancing potentially best- or first-in-class alpha
In the most recent trading session, Bristol Myers Squibb (BMY) closed at $53.25, indicating a +1.33% shift from the previous trading day.
In this article, we will be taking a look at the 20 countries with the highest disease deaths per capita. If you do not want to learn about the global heart disease landscape, head straight to the 5 Countries with the Highest Heart Disease Deaths Per Capita. Heart disease remains a pressing global health concern, […]